J&J Taps UnitedHealth to Accelerate Covid-19 Vaccine Trial

Nov. 13, 2020, 12:00 PM

Johnson & Johnson is turning to data experts at UnitedHealth Group Inc. to accelerate the recruitment of 60,000 participants for the drugmaker’s Covid-19 vaccine trial. Through the partnership, the companies aim to cut the trial time in half.

So far, J&J has enrolled “just a few thousand” patients in its late-stage clinical trial, in part because it lost two weeks when recruitment was paused over a safety concern, Mathai Mammen, head of global research and development at the company’s pharmaceutical division, said in an interview.

The trial resumed in late October, and J&J now expects to have an initial ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.